Breaking News

Glox Therapeutics Awarded Funding to Advance Precision Antibiotics

£500K grant for the development of precision antibiotics targeting AMR lung infections in people with cystic fibrosis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Glox Therapeutics, a developer of precision antibiotic therapies based on naturally occurring bacteriocins, has been awarded £500,000 from Collaborative Discovery Program (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate and LifeArc. Glox Therapeutics will work to accelerate the development of its precision antibiotics to address the growing need for effective treatments to overcome antimicrobial-resistant lung infections in people with cystic fibrosis (CF). Gl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters